Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
Active filters
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Insulin isophane porcine 100units/ml inj 10ml vials
0601012S0AAABAB
|
Insulin isophane | Isophane insulin | Endocrine System | 70 |
|
Insulin isophane human 100units/ml inj 10ml vials
0601012S0AAAEAE
|
Insulin isophane | Isophane insulin | Endocrine System | 42 |
|
Insulin isophane human 100units/ml inj 3ml pf dispos dev
0601012S0AAAIAI
|
Insulin isophane | Isophane insulin | Endocrine System | 28 |
|
Insulin isophane human 100units/ml inj 3ml cartridges
0601012S0AAALAL
|
Insulin isophane | Isophane insulin | Endocrine System | 27 |
|
Insulin isophane porcine 100units/ml inj 3ml cartridges
0601012S0AAATAT
|
Insulin isophane | Isophane insulin | Endocrine System | 26 |
|
Insulin isophane bovine 100units/ml inj 1.5ml cartridges
0601012S0AAANAN
|
Insulin isophane | Isophane insulin | Endocrine System | No data available |
|
Insulin isophane bovine 100units/ml inj 10ml vials
0601012S0AAADAD
|
Insulin isophane | Isophane insulin | Endocrine System | No data available |
|
Insulin isophane bovine 100units/ml inj 3ml cartridges
0601012S0AAASAS
|
Insulin isophane | Isophane insulin | Endocrine System | No data available |
|
Insulin isophane human 100units/ml inj 1.5ml cartridges
0601012S0AAAMAM
|
Insulin isophane | Isophane insulin | Endocrine System | No data available |
|
Insulin isophane human 100units/ml inj 5ml vials
0601012S0AAAQAQ
|
Insulin isophane | Isophane insulin | Endocrine System | No data available |
|
Insulin isophane porcine 100units/ml inj 1.5ml cartridges
0601012S0AAAPAP
|
Insulin isophane | Isophane insulin | Endocrine System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.